Prescribing information

 

LEQVIO®▼ (inclisiran) is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:2,3

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

 

For full safety information, please refer to the GB and NI Summary of Product Characteristics.

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________</

LEQVIO® is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.1

 

This page is intended only for UK healthcare professionals contracted by Novartis to participate in a Novartis promotional activity.

Welcome to the speaker resource centre for LEQVIO. On this page you will find downloadable assets for your Novartis-organised meetings. Please do not distribute these assets.

‘Meeting in a box’ presentations

Inclisiran Patient Search Document thumbnail

How can LEQVIO® ▼ (inclisiran) help when statins alone are not enough?
Lowering LDL-C in Primary Care

Download this meeting-in-a-box which contains a set of slides to enable you to run a meeting on How can LEQVIO® help when statins alone are not enough? Lowering LDL-C in Primary Care. The slide deck offers information about the LDL-C management, information regarding the efficacy and safety profile, dosing and administration of LEQVIO® and specific guidance on the management of patients with dyslipidaemia.

Click here to download the presentation.

 

Inclisiran Patient Search Document thumbnail

How can LEQVIO® ▼ (inclisiran) help when statins alone are not enough?
Lowering LDL-C in Secondary Care

Download this meeting-in-a-box which contains a set of slides to enable you to run a meeting on How can LEQVIO® help when statins alone are not enough? Lowering LDL-C in Secondary Care. The slide deck offers information about the LDL-C management, information regarding the efficacy and safety profile, dosing and administration of LEQVIO® and specific guidance on the management of patients with dyslipidaemia.

Click here to download the presentation.

 

LEQVIO® ▼(inclisiran) master slide library

LEQVIO® master slide library thumbnail

LEQVIO® ▼ (inclisiran) master slide library

Take a deep dive into all aspects of ASCVD and LEQVIO®. This Master Slide library can be used to build your own presentation, following discussion with your Novartis contact and using the guidance provided within. This presentation provides in-depth background information covering everything from the pathophysiology of ASCVD, the importance of LDL-C as a modifiable risk factor as well as the role of LEQVIO in helping patients reach their target LDL-C goals..

Click here to download the presentation.

 

ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; NHS, National Health Service; NICE, National Institute for Health and Care Excellence.

Reference

  1. Leqvio® Summary of Product Characteristics.
Rate this content: 
Average: 1.8 (4 votes)
UK | May 2023 | 285618

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]